BRPI0517227A - forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição - Google Patents
forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condiçãoInfo
- Publication number
- BRPI0517227A BRPI0517227A BRPI0517227-6A BRPI0517227A BRPI0517227A BR PI0517227 A BRPI0517227 A BR PI0517227A BR PI0517227 A BRPI0517227 A BR PI0517227A BR PI0517227 A BRPI0517227 A BR PI0517227A
- Authority
- BR
- Brazil
- Prior art keywords
- isobutanoyloxyethoxy
- alpha
- disease
- condition
- acetic acid
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 title 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 title 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 4
- 239000002552 dosage form Substances 0.000 abstract 2
- 229960002870 gabapentin Drugs 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- -1 isobutanoyloxyethoxy Chemical group 0.000 abstract 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
FORMA DE DOSAGEM ORAL DE LIBERAçãO PROLONGADA DO áCIDO 1- { ¢ALFA-ISOBUTANOILOXIETOXI)CARIBONIL!AMINO METIL}-1-CICLOEXANO ACéTICO, E, MéTODO DE TRATAMENTO DE UMA DOENçA OU CONDIçãO. São apresentadas formas de dosagem oral de liberação prolongada da pró-droga gabapentina, ácido 1 {¢(<244> isobutanoiloxietoxi)carbonil!amino metil}- 1 -cicloexano acético. As formas de dosagens são úteis para o tratamento ou prevenção de doenças e distúrbios para os quais a gabapentina é terapeuticamente eficaz.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62573704P | 2004-11-04 | 2004-11-04 | |
PCT/US2005/040127 WO2006050514A1 (en) | 2004-11-04 | 2005-11-03 | Gabapentin prodrug sustained release oral dosage forms |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0517227A true BRPI0517227A (pt) | 2008-10-14 |
BRPI0517227B1 BRPI0517227B1 (pt) | 2019-09-03 |
BRPI0517227B8 BRPI0517227B8 (pt) | 2021-05-25 |
Family
ID=35929688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517227A BRPI0517227B8 (pt) | 2004-11-04 | 2005-11-03 | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
Country Status (17)
Country | Link |
---|---|
US (8) | US8795725B2 (pt) |
EP (1) | EP1811986B1 (pt) |
JP (2) | JP2008518971A (pt) |
KR (1) | KR101228399B1 (pt) |
CN (2) | CN101068538A (pt) |
AU (1) | AU2005301970B2 (pt) |
BR (1) | BRPI0517227B8 (pt) |
CA (1) | CA2584338C (pt) |
HK (1) | HK1104798A1 (pt) |
IL (1) | IL182964A0 (pt) |
MX (1) | MX2007005306A (pt) |
NO (1) | NO338688B1 (pt) |
NZ (1) | NZ554737A (pt) |
RU (1) | RU2440112C2 (pt) |
TW (1) | TWI377938B (pt) |
WO (1) | WO2006050514A1 (pt) |
ZA (1) | ZA200703571B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
MXPA06002731A (es) * | 2003-09-11 | 2006-06-05 | Xenoport Inc | Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba. |
BRPI0414481A (pt) * | 2003-09-17 | 2006-11-14 | Xenoport Inc | métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica |
KR101096480B1 (ko) * | 2003-10-14 | 2011-12-20 | 제노포트 인코포레이티드 | 감마-아미노부티르산 유사체의 결정질 형태 |
NZ554737A (en) | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
NZ564468A (en) * | 2005-06-20 | 2011-05-27 | Xenoport Inc | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
US20070049627A1 (en) * | 2005-08-23 | 2007-03-01 | Tran Pierre V | Treating vulvodynia using prodrugs of GABA analogs |
WO2007027476A2 (en) * | 2005-08-26 | 2007-03-08 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
US20080161393A1 (en) * | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
US20080206332A1 (en) * | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
KR20110124338A (ko) * | 2009-03-02 | 2011-11-16 | 아스텔라스세이야쿠 가부시키가이샤 | 고형 제제의 포장체 |
AU2010221270B2 (en) * | 2009-03-03 | 2014-02-27 | Xenoport, Inc. | Sustained release oral dosage forms of an R-baclofen prodrug |
US20100226981A1 (en) * | 2009-03-06 | 2010-09-09 | Xenoport, Inc. | Oral dosage forms having a high loading of a gabapentin prodrug |
WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
US20110184060A1 (en) * | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
US20130153459A1 (en) | 2010-09-01 | 2013-06-20 | Kyodo Printing Co., Ltd. | Package |
CN104042597A (zh) * | 2013-03-13 | 2014-09-17 | 苏州朗易生物医药研究有限公司 | 一种治疗神经痛的药物组合物及其制备方法 |
EP3353145B1 (en) | 2015-09-23 | 2022-09-28 | XWPharma Ltd. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
BR102017028213B1 (pt) | 2017-12-27 | 2022-07-19 | Loccitane Do Brasil S.A. | Composição cosmética compreende óleo de licuri, uso da dita composição e método cosmético |
WO2020165633A1 (en) * | 2019-02-11 | 2020-08-20 | Glenmark Pharmaceuticals Limited | A pharmaceutical composition of gabapentin enacarbil or salt thereof |
CN114306234A (zh) * | 2021-12-23 | 2022-04-12 | 江苏百奥信康医药科技有限公司 | 一种含有加巴喷丁复合物的tpgs胶束口服液及其制备方法 |
CN114288246A (zh) * | 2021-12-23 | 2022-04-08 | 江苏百奥信康医药科技有限公司 | 一种含有加巴喷丁复合物的聚合物胶束口服液及其制备方法 |
CN115844834A (zh) * | 2022-11-25 | 2023-03-28 | 江苏百奥信康医药科技有限公司 | 一种加巴喷丁恩那卡比缓释干混悬剂及其制备方法 |
Family Cites Families (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US49626A (en) * | 1865-08-29 | Improvement in grain-driers | ||
US49627A (en) * | 1865-08-29 | Improvement in button-hole sewing-machines | ||
US10453A (en) * | 1854-01-24 | Machinery for fulling cloth | ||
US229361A (en) * | 1880-06-29 | Henry birckenstadt | ||
US198820A (en) * | 1878-01-01 | Improvement in hot-blast ovens | ||
US154057A (en) * | 1874-08-11 | liddell | ||
US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
US3402240A (en) | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
US3139383A (en) | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
GB1364672A (en) | 1971-06-09 | 1974-08-29 | Beecham Group Ltd | Penicillins |
US3962414A (en) | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3811444A (en) | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
DE2336218C3 (de) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4066747A (en) | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
US4189571A (en) | 1978-02-07 | 1980-02-19 | Fisons Limited | Esters of cromoglycates |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4421736A (en) | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
US4760057A (en) | 1983-06-23 | 1988-07-26 | Merck & Co., Inc. | (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
EP0136893B1 (en) | 1983-10-05 | 1989-08-16 | Merck Frosst Canada Inc. | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them |
US4611056A (en) | 1983-10-05 | 1986-09-09 | Merck Frosst Canada, Inc. | Benzo[A]phenothiazines and hydro-derivatives |
EP0138481B1 (en) | 1983-10-05 | 1991-06-26 | Merck Frosst Canada Inc. | Leukotriene biosynthesis inhibitors |
US4916230A (en) | 1984-07-02 | 1990-04-10 | Merck & Co., Inc. | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
US4820523A (en) | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
US4752470A (en) | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US4816263A (en) | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
US4853229A (en) | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
PH26730A (en) | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
US5084169A (en) | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
EP0458751A1 (en) | 1990-05-25 | 1991-11-27 | Warner-Lambert Company | Delivery system for cyclic amino acids with improved taste, texture and compressibility |
US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
GB9204918D0 (en) | 1992-03-06 | 1992-04-22 | Nycomed As | Chemical compounds |
RU2140901C1 (ru) | 1992-05-20 | 1999-11-10 | Нортвестерн Юниверсити | АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ |
AU4534593A (en) | 1992-06-12 | 1994-01-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
US5466811A (en) | 1994-07-18 | 1995-11-14 | Merck & Co., Inc. | Dioxolenylmethyl carbamates pro moieties for amine drugs |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5684018A (en) | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
US5672584A (en) | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
WO1996038435A1 (en) | 1995-05-30 | 1996-12-05 | Abbott Laboratories | Dopamine agonists |
PL328432A1 (en) | 1996-02-07 | 1999-02-01 | Warner Lambert Co | Novel cyclic amino acids as pharmaceutic agents |
IL125364A0 (en) | 1996-03-14 | 1999-03-12 | Warner Lambert Co | Novel bridged cyclic amino acids and pharmaceutical compositions containing them |
GEP20012413B (en) | 1996-03-14 | 2001-04-25 | Warner Lambert Co | Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents |
WO1998003167A1 (en) | 1996-07-24 | 1998-01-29 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
SK8599A3 (en) | 1996-07-30 | 2000-03-13 | Arris Pharm Corp | Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal |
US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
CA2263663C (en) | 1996-10-23 | 2006-05-30 | Justin Stephen Bryans | Substituted gamma aminobutyric acids as pharmaceutical agents |
CA2294126A1 (en) | 1997-06-26 | 1999-01-07 | Douglas Wade Beight | Antithrombotic agents |
US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
CA2303244C (en) | 1997-10-27 | 2005-12-06 | Warner-Lambert Company | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
WO1999031074A2 (en) | 1997-12-16 | 1999-06-24 | Warner-Lambert Company | ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders |
CA2304967C (en) | 1997-12-16 | 2005-06-14 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
CN1495160A (zh) | 1997-12-16 | 2004-05-12 | ��ʲ | 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
EP1047414A1 (en) | 1998-01-23 | 2000-11-02 | Warner-Lambert Company | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
JP2002516312A (ja) | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | カルシウムチャンネルのα2δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物 |
FR2779651B1 (fr) | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
ES2228087T3 (es) | 1998-09-14 | 2005-04-01 | Warner-Lambert Company Llc | Acidos (alquilo ramificado)-pirrolidin-3-carboxilicos. |
ES2279631T3 (es) | 1998-10-16 | 2007-08-16 | Warner-Lambert Company Llc | Uso de analogos de gaba para la fabricaion de un medicamento para el tratamiento de mania y trastornos bipolares. |
US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
US6716453B1 (en) * | 1999-05-20 | 2004-04-06 | Verion, Inc. | Method for increasing the active loading of compressible composition forms |
AU3313900A (en) | 1999-05-27 | 2000-12-18 | Pfizer Products Inc. | Mutual prodrugs of amlodipine and atorvastatin |
DE60034344T2 (de) | 1999-07-22 | 2008-01-10 | University Of Rochester | Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen |
MXPA01008085A (es) | 1999-12-08 | 2002-04-24 | Warner Lambert Co | Inhibidores de aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de la retinopatia diabetica. |
CA2397831A1 (en) | 2000-01-28 | 2001-08-02 | Rohm And Haas Company | Enhanced propertied pharmaceuticals |
WO2001062242A1 (en) | 2000-02-24 | 2001-08-30 | Biocryst Pharmaceuticals, Inc. | Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
WO2001090081A1 (en) | 2000-05-25 | 2001-11-29 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
EP1296671B1 (en) | 2000-06-26 | 2008-03-26 | Warner-Lambert Company LLC | Gabapentin analogues for sleep disorders |
DE60118195T2 (de) | 2000-07-07 | 2006-12-14 | Novo Nordisk A/S | Modulatoren von protein tyrosin phosphatasen (ptpasen) |
WO2002004458A1 (en) | 2000-07-07 | 2002-01-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
GB0018528D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
JP2004510716A (ja) * | 2000-10-02 | 2004-04-08 | ユーエスヴイ リミテッド | メトフォルミン含有持続性放出薬理組成物とその製造方法 |
EP1358200A4 (en) | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACID TO IMPROVE THE ORAL ABSORPTION AND SYSTEMIC BIOVERABILITY OF MEDICAMENTS |
EP1361847A2 (en) | 2000-10-06 | 2003-11-19 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
EP1333807A4 (en) | 2000-10-13 | 2005-06-29 | Advancis Pharmaceuticals | ERYTHROMYCIN DERIVATIVES WITH PROLONGED RELEASE |
DK1383731T3 (da) | 2000-10-20 | 2009-12-07 | Biocryst Pharm Inc | Biarylforbindelser som serinproteaseinhibitorer |
GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
AU2002239257A1 (en) | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
CZ20032764A3 (cs) * | 2001-04-19 | 2004-04-14 | Warner-Lambert Company | Fúzní bicyklické nebo tricyklické aminokyseliny |
MXPA03011096A (es) | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
WO2002100347A2 (en) | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
AU2002316237A1 (en) | 2001-06-13 | 2002-12-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
CA2452738C (en) | 2001-07-04 | 2011-06-14 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
EP2332550A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of neurodegenerative diseases |
US7109231B2 (en) | 2001-08-09 | 2006-09-19 | Eli Lilly And Company | Cyclohept[b]indole derivatives |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
JP2005516020A (ja) * | 2001-12-20 | 2005-06-02 | ファルマシア・コーポレーション | ゼロ次持続放出剤形およびその製造方法 |
EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
US20050158380A1 (en) | 2002-06-07 | 2005-07-21 | Manish Chawla | Sustained release oral dosage forms of gabapentin |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20060147527A1 (en) * | 2002-12-13 | 2006-07-06 | Cilag Ag | Controlled release preparations comprising tramadol and topiramate |
NZ543138A (en) | 2003-03-31 | 2009-02-28 | Xenoport Inc | Treating or preventing hot flashes using prodrugs of GABA analogs |
WO2005010011A2 (en) | 2003-07-15 | 2005-02-03 | Xenoport, Inc. | Methods of synthesis of acyloxyalkyl compounds |
PT1660440E (pt) | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
MXPA06002731A (es) | 2003-09-11 | 2006-06-05 | Xenoport Inc | Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba. |
BRPI0414481A (pt) | 2003-09-17 | 2006-11-14 | Xenoport Inc | métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica |
KR101096480B1 (ko) | 2003-10-14 | 2011-12-20 | 제노포트 인코포레이티드 | 감마-아미노부티르산 유사체의 결정질 형태 |
CA2551859C (en) | 2003-12-30 | 2011-10-04 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
NZ554737A (en) | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
US20070049627A1 (en) | 2005-08-23 | 2007-03-01 | Tran Pierre V | Treating vulvodynia using prodrugs of GABA analogs |
WO2007027476A2 (en) | 2005-08-26 | 2007-03-08 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
EA200970483A1 (ru) | 2006-11-14 | 2009-12-30 | Ксенопорт, Инк. | Применение пролекарств габапентина и прегабалина для лечения шума в ушах |
US20080161393A1 (en) | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
US20080206332A1 (en) | 2007-01-11 | 2008-08-28 | Kidney David J | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
-
2005
- 2005-11-03 NZ NZ554737A patent/NZ554737A/en active IP Right Revival
- 2005-11-03 RU RU2007120570/15A patent/RU2440112C2/ru not_active IP Right Cessation
- 2005-11-03 WO PCT/US2005/040127 patent/WO2006050514A1/en active Application Filing
- 2005-11-03 CN CNA2005800409309A patent/CN101068538A/zh active Pending
- 2005-11-03 US US11/269,045 patent/US8795725B2/en active Active
- 2005-11-03 CA CA2584338A patent/CA2584338C/en active Active
- 2005-11-03 CN CN201110407890.4A patent/CN102429882B/zh not_active Expired - Fee Related
- 2005-11-03 MX MX2007005306A patent/MX2007005306A/es active IP Right Grant
- 2005-11-03 JP JP2007539363A patent/JP2008518971A/ja not_active Withdrawn
- 2005-11-03 AU AU2005301970A patent/AU2005301970B2/en not_active Ceased
- 2005-11-03 BR BRPI0517227A patent/BRPI0517227B8/pt active IP Right Grant
- 2005-11-03 EP EP05826200.7A patent/EP1811986B1/en active Active
- 2005-11-03 KR KR1020077010201A patent/KR101228399B1/ko active IP Right Grant
- 2005-11-04 TW TW094138865A patent/TWI377938B/zh not_active IP Right Cessation
-
2007
- 2007-05-03 ZA ZA2007/03571A patent/ZA200703571B/en unknown
- 2007-05-03 IL IL182964A patent/IL182964A0/en unknown
- 2007-05-31 NO NO20072767A patent/NO338688B1/no not_active IP Right Cessation
- 2007-12-05 HK HK07113271.6A patent/HK1104798A1/xx not_active IP Right Cessation
-
2013
- 2013-02-25 JP JP2013034943A patent/JP5856095B2/ja active Active
-
2014
- 2014-06-19 US US14/309,662 patent/US8906412B2/en active Active
- 2014-11-04 US US14/532,854 patent/US20150072004A1/en not_active Abandoned
-
2016
- 2016-11-22 US US15/359,321 patent/US9949941B2/en active Active
-
2018
- 2018-03-19 US US15/925,013 patent/US20180207117A1/en not_active Abandoned
- 2018-12-10 US US16/215,318 patent/US20190247345A1/en not_active Abandoned
-
2019
- 2019-10-15 US US16/653,746 patent/US20200147019A1/en not_active Abandoned
-
2020
- 2020-06-25 US US16/912,123 patent/US20200323804A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517227A (pt) | forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição | |
BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
HK1117824A1 (en) | Acyloxyalkyl carbamate prodrugs of tranexamic acid and use | |
WO2009093119A3 (en) | Use of serine protease inhibitors in the treatment of skin diseases | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
WO2005019163A3 (en) | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | |
DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
ATE511392T1 (de) | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit | |
WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
ATE412414T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen | |
WO2006050472A3 (en) | Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids | |
WO2005027977A3 (en) | Diclofenac compositions for the treatment of skin disorders | |
WO2006050471A3 (en) | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use | |
CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
WO2005067931A3 (en) | Dopamine uptake inhibitors for the treatment of neurological disease | |
WO2006079077A3 (en) | Use of diltiazem or analogs thereof as modulators of ghrelin receptor | |
WO2008013860A3 (en) | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use | |
DE602004008658D1 (de) | Behandlung neurodegenerativer krankheiten | |
EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
BRPI0509881A (pt) | combinação terapêutica para tratamento da doença de alzheimer | |
JP2014532711A5 (pt) | ||
JP2012519671A5 (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |